Hepatocellular carcinoma (HCC) represents approximately 6% of all new cancer cases diagnosed worldwide, with more than half of these occurring in China alone ([Parkin *et al*, 2005](#bib9){ref-type="other"}). Relatively high incidence rates are also found in South Eastern Asia and in sub-Saharan Africa ([Parkin *et al*, 2005](#bib9){ref-type="other"}). One of the least curable malignancies, HCC is the third most frequent cause of cancer death among men worldwide ([Parkin *et al*, 2005](#bib9){ref-type="other"}).

Chronic infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most important causes of HCC ([IARC, 1994](#bib4){ref-type="other"}). According to the World Health Organisation (WHO), approximately 350 million people are chronically infected with HBV ([WHO, 2004](#bib12){ref-type="other"}) and 170 million with HCV ([WHO and the Viral Hepatitis Prevention Board, 1999](#bib10){ref-type="other"}) worldwide. There are no comparable statistics for the number of individuals coinfected with both HBV and HCV.

The relative importance of HBV and HCV infections in HCC aetiology is known to vary greatly from one part of the world to another ([Parkin, 2006](#bib8){ref-type="other"}), and can change over time ([Lu *et al*, 2006](#bib6){ref-type="other"}). In order to investigate this issue, we collated all published data on the prevalence of chronic HBV and HCV infection among HCC cases.

MATERIALS AND METHODS
=====================

MEDLINE and WHO regional indexed databases were used to search for articles published from 1 January 1989 (after HCV testing became available) to 31 October 2006, by means of the MeSH terms: 'hepatocellular carcinoma\', 'hepatitis B virus\' and 'hepatitis C virus or hepacvirus\'. Additional relevant studies were identified in the reference lists of selected articles. No language limitation was imposed. Eligible studies had to report prevalence of both hepatitis B surface antigen (HBsAg) and antibodies against HCV (anti-HCV), alone and in combination, for at least 20 HCC cases. To avoid multiple inclusions of the same HCC cases in more than one article, the time and place of recruitment of cases were cross-checked and the most recent publication was used. In the event that study methods indicated the availability of HBsAg and anti-HCV prevalence data but did not report both of them and the percent of coinfection in the article, authors were contacted for the supplementary information. In the course of contacting authors, additional data became available from one study expanded since the original publication ([Appendix A](#app1){ref-type="app"}).

The key information extracted from each study were study country, gender distribution, generation of HCV serology tests used, prevalence of HBsAg alone (HBsAg^+^) and anti-HCV alone (anti-HCV^+^) and in combination (HBV/HCV coinfection), and the number of cases that were seronegative for both viral markers.

Key information on 110 selected studies is given in the [Appendix A](#app1){ref-type="app"} by continent and country. For multicentric studies, HBsAg^+^ and anti-HCV^+^ prevalence data were separated by country ([Appendix A](#app1){ref-type="app"}). Study size varied substantially and four reports (one each from China, Japan, Taiwan and the United States) included more than 1000 HCC cases. With respect to anti-HCV testing, 17 studies (published from 1989 to 1994) reported the use of first-generation enzyme-linked immunoabsorbant assay (ELISA), 29 studies (published from 1992 to 2003) second-generation ELISA and 42 studies (published from 1997 to 2006) third-generation ELISA. Nineteen studies did not report the generation of HCV testing used; four of these were assumed to have used first-generation ELISA based on date of publication or patient admission. Studies known or likely to have used first-generation ELISA were not included in the computation of HCV prevalence owing to known problems of sensitivity and specificity of those assays ([Booth *et al*, 2001](#bib3){ref-type="other"}). Two studies used HCV RNA instead of anti-HCV, and were included in the analysis ([Appendix A](#app1){ref-type="app"}).

RESULTS
=======

After exclusion of studies using first-generation ELISA for anti-HCV testing, there were 90 studies with relevant data on the prevalence of HBsAg and anti-HCV, covering 27 881 HCC cases from 36 countries ([Table 1](#tbl1){ref-type="table"}). The majority of cases were from Asia (66%) followed by the Americas (15%), Europe (12%) and Africa (7%). In [Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}, HBsAg^+^ and anti-HCV^+^ prevalence data are shown for countries with information on at least 150 HCC cases. Otherwise countries from the same continent were combined. Substantial variations in HBsAg and anti-HCV prevalence were observed between countries and continents.

Asia
----

The largest number of HCC cases from any single country in Asia came from Taiwan, with 8595 HCC cases identified from a single multicentre study ([Lu *et al*, 2006](#bib6){ref-type="other"}), Japan and China ([Figure 1](#fig1){ref-type="fig"}). The proportion of HBsAg^+^ HCC cases was greater than 50% in China, Taiwan, Korea, Thailand, Vietnam and Turkey. The lowest proportion of HBsAg^+^ HCC cases was reported in Japan where there was a strong predominance of anti-HCV seropositivity in HCC cases (68%). A higher proportion of anti-HCV^+^ than HBsAg^+^ HCC cases was also found in Pakistan (45%), and in Mongolia (40%), where HBV/HCV coinfection was also very frequent (25%). In China, anti-HCV was found twice as often in combination with HBsAg than alone. The highest proportion of HCC cases seronegative for both hepatitis viruses was found in India (37%).

Europe
------

The countries in Europe where the largest numbers of HCC cases were studied were Italy, Greece and Germany ([Figure 2](#fig2){ref-type="fig"}). The proportion of HBsAg^+^ HCC cases (56%) was higher than that of anti-HCV^+^ HCC in Greece, whereas the opposite was observed everywhere else in Europe. In Italy and Spain, the proportions of anti-HCV^+^ HCC cases were 43 and 48%, respectively. Seropositivity for anti-HCV was significantly higher than for HBsAg also in Austria and Sweden, whereas in Germany the seroprevalence of the two viruses was similar. Hepatitis B virus/HCV coinfection was rare in most European studies, whereas HCC cases seronegative for both hepatitis viruses were relatively common, measuring over 80% in Sweden.

The Americas
------------

A majority of American studies on HCC and hepatitis viruses were conducted in the United States ([Figure 3](#fig3){ref-type="fig"}), with two-thirds of HCC cases coming from a nation-wide linkage study for the Surveillance Epidemiology and End-Results Program. In the United States, 9% of HCC cases were HBsAg^+^ and 22% were anti-HCV^+^. The prevalence of HBV/HCV coinfection in HCC cases was 3.2% and a high proportion (67%) of HCC cases were seronegative for markers of both hepatitis viruses. In Brazil, 37 and 18% of HCC cases were HBsAg^+^ and anti-HCV^+^, respectively. Only 207 additional HCC cases were available from other American countries (Peru and Mexico), where prevalence of HBsAg exceeded that of anti-HCV.

Africa
------

Nearly half of the data on HCC in Africa came from Egypt ([Figure 3](#fig3){ref-type="fig"}), where a very high proportion (69%) of HCC cases was anti-HCV^+^. All other African countries showed a preponderance of HBsAg seropositivity. HBV/HCV coinfection did not exceed 10% anywhere in Africa, whereas approximately 30% of HCC cases were seronegative for both hepatitis viruses in South Africa and Mozambique.

DISCUSSION
==========

This review, based on nearly 30 000 HCC cases, confirms wide international variation in the relative importance of HBV and HCV in this disease. As expected, HBV infection was found substantially more often than HCV infection in HCC cases from the majority of Asian and African countries with the available data. Conversely, more HCC cases were found to be anti-HCV^+^ than HBsAg^+^ in Europe and in the United States, as was also the case in Japan, Pakistan and Mongolia, and in Asia generally. In some countries (i.e., China and Mongolia), more than 10% of HCC cases were coinfected with both hepatitis viruses, thus hampering the attribution of a fraction of HCC cases to HBV or HCV.

More than half of HCC cases were both HBsAg^−^ and anti-HCV^−^ in the United States and some North European countries, thus pointing to the relative importance of heavy alcohol consumption and, possibly, smoking, obesity and diabetes mellitus ([Yuan *et al*, 2004](#bib13){ref-type="other"}) in areas where hepatitis virus prevalence and HCC incidence are low.

Our systematic review failed to identify information on HBV and HCV infection among HCC cases in Eastern Europe, Russia, Central Asia and the majority of African and Latin American countries. None of the studies we found from Oceania using second- or third-generation ELISA met our inclusion criteria. However, a record-linkage study from New South Wales, Australia showed a similar proportion of HBsAg^+^ (45%) and anti-HCV^+^ (53%) HCCs and low frequency of HBV/HCV coinfection (2%) among 281 virus-related HCC cases ([Amin *et al*, 2006](#bib2){ref-type="other"}).

In addition to lack of data from many parts of the world, some weaknesses of our present review should be borne in mind. The extent to which the HCC cases we reported upon are representative, at a national level, is unclear, especially where only small studies were available. Furthermore, important secular trends may be concealed by our analysis, as in the largest study identified ([Lu *et al*, 2006](#bib6){ref-type="other"}), which showed a steady increase in the proportion of HCC cases related to HCV in the last two decades in Taiwan. The vast majority of studies did not provide information on occult HBV infection. Occult HBV infection seems, however, to have little or no clinical significance, at least among immunocompetent individuals ([Knoll *et al*, 2006](#bib5){ref-type="other"}). Most importantly, owing to the long latent period of HCC, seropositivity among HCC cases does not reflect the current importance of the two viruses in the relevant population but rather that two or three decades earlier.

Based upon prevalence of the infections in different populations around the world and a relative risk of 20 for both viruses, [Parkin (2006)](#bib8){ref-type="other"} estimated the fraction of HCC attributable to HBV and HCV in 2002 to be, respectively, 23 and 20% in developed countries and 59 and 33% in developing countries. Our simpler approach, based on HCC cases only, was mainly dictated by the wish to use information from many world populations for whom information on HCC was available but not data on population prevalences of HBV and HCV. It suggests, however, that the relative contribution of HCV to the current HCC burden in middle-aged and old individuals in developed countries and in some developing countries might be higher than in [Parkin (2006)](#bib8){ref-type="other"}. In fact, seroprevalence surveys on which attributable risks are based tend to over-sample young individuals at low risk of HCV infection (e.g., blood donors and pregnant women, [WHO, 1999](#bib11){ref-type="other"}; [Madhava *et al*, 2002](#bib7){ref-type="other"}). In conclusion, our findings underline the importance of the prevention of HCV infection that, in the absence of a vaccine, will require an integrated strategy including screening of blood donations, safe injection practices and avoidance of unnecessary injections [(Ahmad, 2004](#bib1){ref-type="other"}).
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![Seroprevalence and corresponding 95% confidence intervals of HBsAg, anti-HCV, both and negative in patients with HCC in Asia. ^\*^Indonesia, Myanmar, Iran, Lebanon and Saudi Arabia.](6603649f1){#fig1}
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###### 

Continent-specific distribution of studies with HCC cases^a^

  **Continent**    **No. of studies**   **HCC cases**  **Countries represented**
  --------------- -------------------- --------------- ---------------------------------------------------------------------------------------------------------------------------------------
  Asia                     47              18 400      China, India, Indonesia, Iran, Japan, Korea, Lebanon, Mongolia, Myanmar, Pakistan, Saudi Arabia, Taiwan, Thailand, Turkey and Vietnam
  Europe                   22               3469       Austria, Belgium, Germany, Greece, Italy, Sweden, Spain and UK
  Americas                 12               4148       United States, Brazil, Peru and Mexico
  Africa                   12               1864       Egypt, Gambia, Mozambique, Niger, Nigeria, Senegal, South Africa, Somalia and Sudan
  Total                  90^b^             27 881       

Studies that used first-generation ELISA for anti-HCV detection were excluded.

Total does not add up to 90 owing to three multi-continent studies.

                                                                                                               **Cases**   **Prevalence (%)**                                         
  ------------------------ ----------------------------------------------------------------- ---------------- ----------- -------------------- ------ ---------- ---------- --------- ----------
  ASIA                                                                                                                                                                                
  Shi J                    *Br J Cancer* 2005; **92**: 607--612                              China               3126             ---           ---      59.6       7.4       14.1       18.9
  Ding X^c^                *Jpn J Inf Dis* 2003; **56**: 19--22                              China                112              98            14      66.1       2.7        1.8       29.5
  Wang BE                  *J Med Virol* 2002; **67**: 394--400                              China                92              ---           ---      67.4       4.3        6.5       21.7
  Zhang JY                 *Int J Epidemiol* 1998; **27**: 574--578                          China                152             136            16      55.3       3.3        7.9       33.6
  Yu SZ                    *Zhonghua Liu Xing Bing Xue Za Zhi* 1997; **18**: 214--216        China                340             ---           ---      54.1       5.9       12.4       27.6
  Yuan JM                  *Int J Cancer* 1995; **63**: 491--493                             China                76               76            0       64.5       0.0        1.3       34.2
  Okuno H                  *Cancer* 1994; **73**: 58--62                                     China                186             168            18      65.6       0.5        4.8       29.0
  Tao QM^a^                *Gastroenterol Jpn* 1991; **26**: (Suppl 3) 156--158              China                52              ---           ---      38.5       9.6       28.8       23.1
  Leung NW^a^              *Cancer* 1992; **70**: 40--44                                     Hong Kong            424             381            43      76.9       3.8        3.5       15.8
  Joshi N                  *Trop Gastroenterol* 2003; **24**: 73--75                         India                40               33            7       47.5       20.0       0.0       32.5
  Wang BE                  *J Med Virol* 2002; **7**: 394--400                               India                15               11            4       26.7       53.3       0.0       20.0
  Sarin SK                 *J Gastroenterol Hepatol* 2001; **16**: 666--673                  India                74               63            11      63.5       4.1        8.1       24.3
  Ramesh R                 *J Gastroenterol Hepatol* 1992; **7**: 393--395                   India                53               45            8       22.6       9.4        5.7       62.3
  Wang BE                  *J Med Virol* 2002; **67**: 394--400                              Indonesia            47              ---           ---      21.3       40.4       2.1       36.2
  Budihusodo U^a^          *Gastroenterol Jpn* 1991; **26** (Suppl 3): 196--201              Indonesia            64              ---           ---      29.7       50.0      15.6       4.7
  Hajiani E                *Saudi Med J* 2005; **26**: 974--977                              Iran                 71               45            26      52.1       8.5         0        39.4
  Ding X^c^                *Jpn J Inf Dis* 2003; **56**: 19--22                              Japan                122              88            34      27.9       59.8       9.0       3.3
  Sharp GB                 *Int J Cancer* 2003; **103**: 531--537                            Japan                159             ---           ---      37.7       24.5       8.8       28.9
  Miyazawa K               *Intervirology* 2003; **46**: 150--156                            Japan                250             196            54      11.6       80.4       1.2       6.8
  Wang BE                  *J Med Virol* 2002; **67**: 394--400                              Japan                191             140            51      17.8       70.2       1.0       11.0
  Tanioka H                *J Infect Chemother* 2002; **8**: 64--69                          Japan               1019             709           310      16.4       72.6       0.9       10.1
  Fukuhara T               *J Radiat Res* (Tokyo) 2001; **42**: 117--130                     Japan                168             ---           ---      21.4       36.3      11.3       31.0
  Koike Y                  *Hepatology* 2000; **32**: 1216--1223                             Japan                236             164            72      9.7        79.7       0.4       10.2
  Abe K                    *Hepatology* 1998; **28**: 568--572                               Japan                122              89            33      18.0       61.5       4.9       15.6
  Tanaka K                 *J Natl Cancer Inst* 1996; **88**: 742--746                       Japan                91               73            18      18.7       75.8       2.2       3.3
  Shiratori Y              *Hepatology* 1995; **22**: 1027--1033                             Japan                205             163            42      11.2       83.4       1.0       4.4
  Suga M                   *Hepatogastroenterology* 1994; **41**: 438--441                   Japan                63               51            12      27.0       54.0       9.5       9.5
  Eto H                    *Southeast Asian J Trop Med Public Health* 1994; **25**: 88--92   Japan                89               69            20      23.6       65.2       3.4       7.9
  Kiyosawa K^a^            *Cancer Chemother Pharmacol* 1992; **31**                         Japan                162             ---           ---      13.0       77.8       3.1       6.2
                           (Suppl): S150--S156                                                                    267             225            42      30.7       59.6       1.5       8.2
                                                                                                                  112              94            18      53.6       33.9       4.5       8.0
  Yuki N^a^                *Dig Dis Sci* 1992; **37**: 65--72                                Japan                148             126            22      17.6       61.5       8.1       12.8
  Nishioka K^b^            *Cancer* 1991; **67**: 429--433                                   Japan                180             ---           ---      35.6       44.4       6.1       13.9
  Saito I^a^               *Proc Natl Acad Sci* 1990; **87**: 6547--6549                     Japan                253             207            46      19.4       53.8       0.8       26.1
  Ding X^c^                *Jpn J Inf Dis* 2003; **56**: 19--22                              Korea                55               42            13      69.1       5.5        3.6       21.8
  Kwon SY                  *J Gastroenterol Hepatol* 2000; **15**: 1282--1286                Korea                26              ---           ---      61.5       15.4       0.0       23.1
  Abe K                    *Hepatology* 1998; **28**: 568--572                               Korea                55               42            13      81.8       5.5        3.6       9.1
  Shin HR                  *Int J Epidemiol* 1996; **25**: 933--940                          Korea                170             ---           ---      65.3       10.0       1.2       23.5
  Park BC                  *J Viral Hepat* 1995; **2**: 195--202                             Korea                540             431           109      58.1       11.3       3.0       27.6
  Pyong SJ^a^              *Jpn J Cancer Res* 1994; **85**: 674--679                         Korea                90               68            22      15.6       73.3       1.1       10.0
  Yaghi C                  *World J Gastroenterol* 2006; **2**: 3575--3580                   Lebanon              92               78            14      64.1       16.3       3.3       16.3
  Tsatsralt-Od B^c^        *J Med Virol* 2005; **77**: 491--499                              Mongolia             76               46            30      17.1       14.5      68.4        0
  Shizuma T                *Kansenshogaku Zasshi* 2005; **79**: 824--825                     Mongolia             90              ---           ---      34.4       48.9       5.6       11.1
  Oyunsuren T              *Asian Pac J Cancer Prev* 2006; **7**: 460--462                   Mongolia             197             110            87      30.3       39.7      25.1       5.0
  Nakai K                  *J Clin Microbiol* 2001; **39**: 1536--1539                       Myanmar              25              ---           ---      56.0       24.0      12.0       8.0
  Hamza H                  *Proc World Congress of Epidemiology* 2005                        Pakistan             57               40            17      21.1       43.9       7.0       28.1
  Khokhar N                *J Ayub Med Coll Abbottabad* 2003; **15**: 1--4                   Pakistan             57               45            12      15.8       47.4       3.5       33.3
  Sharieff S               *Trop Doct* 2001; **31**: 224--225                                Pakistan             201             149            52      35.8       41.3       7.0       15.9
  Mumtaz MS                *J Rawal Med Coll* 2001; 5: 78--80                                Pakistan             44              ---           ---      25.0       54.5       6.8       13.6
  Kausar S                 *Pak J Gastroenterol* 1998; **12**: 1--2                          Pakistan             30              ---           ---      16.7       73.3       6.7       3.3
  Butt AK                  *J Pak Med Assoc* 1998; **48**: 197--201                          Pakistan             76               65            11      10.5       75.0      10.5       3.9
  Abdul Mujeeb S           *Trop Doct* 1997; **27**: 45--46                                  Pakistan             54              ---           ---      42.6       9.3       24.1       24.1
  Tong CY                  *Epidemiol Infect* 1996; **117**: 327--332                        Pakistan             23               22            1       78.3       4.3        4.3       13.0
  Ayoola EA                *J Gastroenterol Hepatol* 2004; **19**: 665--669                  Saudi Arabia         118              96            22      63.6       8.5        3.4       24.6
  Al Karawi MA^a^          *J Gastroenterol Hepatol* 1992; **7**: 237--239                   Saudi Arabia         42               38            4       33.3       26.2       4.8       35.7
  Khan LA                  *Saudi Med J* 2001; **22**: 641--642                              Saudi Arabia         24               23            1       20.8       25.0       4.2       50.0
  Ozer B                   *Turk J Gastroenterol* 2003; **14**: 85--90                       Turkey               35               28            7       65.7       28.6       2.9       2.9
  Uzunalimoglu O           *Dig Dis Sci* 2001; **46:** 1022--1028                            Turkey               207             163            44      52.2       19.3       3.9       24.6
  Lu SN                    *Int J Cancer* 2006; **119**: 1946--1952                          Taiwan              8595             6741          1854     53.2       27.9       8.3       10.7
  Tangkijvanich P          *J Gastroenterol* 1999; **34**: 227--233                          Thailand             86               69            17      58.1       10.5       8.1       23.3
  Tangkijvanich P          *J Gastroenterol* 2003; **38**: 142--148                          Thailand             101              86            15      56.4       5.0        8.9       29.7
  Songsivilai S            *Trans R Soc Trop Med Hyg* 1996; **90**: 505--507                 Thailand             80              ---           ---      60.0       10.0       3.8       26.2
  Ding X^c^                *Jpn J Inf Dis* 2003; **56**: 19--22                              Vietnam              38               30            8       60.5       2.6         0        36.8
  Cordier S                *Int J Cancer 1993*; **55**: 196--201                             Vietnam              149             149            0       92.6       2.0         0        5.4
  **Continent subtotal**                                                                                       **20194**                               **48.1**   **29.2**   **7.9**   **14.8**
                                                                                                                                                                                           
  EUROPE                                                                                                                                                                              
  Schoniger-Hekele M       *Gut* 2001; **48**: 103--109                                      Austria              245             187            58      9.8        36.7       1.6       51.8
  Van Roey G               *Eur J Gastroenterol Hepatol* 2000; **12**: 61--66                Belgium              124             ---           ---      21.0       23.4      16.9       38.7
  Nalpas B^b^              *J Hepatol* 1991; **12**: 70--74                                  France               47              ---           ---      6.4        42.6      19.1       31.9
  Erhardt A                *Dtsch Med Wochenschr* 2002; **127**: 2665--2668                  Germany              192             ---           ---      21.4       34.9       4.7       39.1
  Rabe C                   *World J Gastroenterol* 2001; **7**: 208--215                     Germany              85               64            21      29.4       24.7       7.1       38.8
  Hellerbrand C            *Dig Dis* 2001; **19**: 345--51                                   Germany              118              94            24      7.6        19.5       0.0       72.9
  Kubicka S                *Liver* 2000; **20**: 312--318                                    Germany              268             214            54      25.0       16.8      10.1       48.1
  Petry W                  *Z Gastroenterol* 1997; **35**: 1059--1067                        Germany              55              ---           ---      20.0       52.7       0.0       27.3
  Goeser T                 *Cancer Epidemiol Biomarkers Prev* 1994; **3**: 311--315          Germany              81               66            15      27.2       24.7       1.2       46.9
  Raptis I                 *J Viral Hepat* 2003; 10: 450--454                                Greece               306             265            41      52.3       21.9       0.7       25.2
  Kuper HE                 *Cancer Causes Control* 2000; **11**: 171--175                    Greece               333             283            50      59.5       12.3       3.3       24.9
  Hadziyannis S            *Int J Cancer* 1995; **60**: 627--631                             Greece               65               49            16      56.9       7.7        4.6       30.8
  Kaklamani E^a^           *JAMA* 1991; **265**:1974--1976                                   Greece               185             166            19      22.7       15.7      23.2       38.4
  Franceschi S             *Cancer Epidemiol Biomarkers Prev* 2006; **15**: 683--689         Italy                229             183            46      10.0       61.1       3.9       24.9
  Donato F                 *Oncogene* 2006; **25**: 3756--3770                               Italy                583             ---           ---      19.7       37.9       2.7       39.6
  Ricci G                  *Cancer Lett* 1995; **98**: 121--125                              Italy                104             ---           ---      31.7       20.2      34.6       13.5
  Stroffolini T            *J Hepatol* 1992; **16**: 360--363                                Italy                65               47            18      16.9       58.5       7.7       16.9
  Simonetti RG^a^          *Ann Intern Med* 1992; **116**: 97--102                           Italy                212             161            51      7.1        62.7       8.5       21.7
  Levrero M^b^             *J Hepatol* 1991; **12**: 60--63                                  Italy                167             135            32      22.8       49.1       9.0       19.2
  Colombo M^a^             *Lancet* 1989; **2**: 1006--1008                                  Italy                132             115            17      14.4       48.5      16.7       20.5
  Ladero JM                *Eur J Cancer* 2006; **42**: 73--77                               Spain                184             150            34      4.9        63.0       1.6       30.4
  Rodriguez Vidigal FF     *An Med Interna* 2005; **22**: 162--166                           Spain                42               37            5       11.9       42.9       0.0       45.2
  Ding X^c^                *Jpn J Inf Dis* 2003; **56**: 19--22                              Spain                57               45            12      38.6       12.3       3.5       45.6
  Crespo J                 *Med Clin (Barc)* 1996; **106**: 241--245                         Spain                94               82            12      18.1       43.6      10.6       27.7
  Bruix J^a^               *Lancet* 1989; **2**: 1004--1006                                  Spain                96               67            29      4.2        69.8       5.2       20.8
  Widell A                 *Scand J Infect Dis* 2000; **32**: 147--152                       Sweden               95              ---           ---      5.3        16.8        0        77.9
  Kaczynski J              *Scand J Gastroenterol* 1996; **31**: 809--813                    Sweden               64               48            16       0         10.9        0        89.1
  Haydon GH                *Gut* 1997; **40**: 128--132                                      United Kingdom       80              ---           ---      16.3       27.5       2.5       53.8
  **Continent subtotal**                                                                                       **4308**                                **23.1**   **34.3**   **6.5**   **36.1**
                                                                                                                                                                                           
  AFRICA                                                                                                                                                                              
  Ezzat S^d^               *Int J Hyg Environ* Health 2005; **208**: 329--339                Egypt                450             ---           ---      3.8        82.0       5.3       8.9
  Abdel--Wahab M           *Hepatogastroenterology* 2000; **47**: 663--668                   Egypt                385             ---           ---      14.5       61.0       7.0       17.4
  Hassan MM                *J Clin Gastroenterol* 2001; **33**: 123--126                     Egypt                33               23            10      12.1       72.7       3.0       12.1
  Darwish MA               *J Egypt Public Health Assoc* 1993; **68**: 1--9                  Egypt                70               57            13      21.4       30.0      40.0       8.6
  Kirk GD                  *Hepatology* 2004; **39**: 211--219                               Gambia               186             ---           ---      59.1       15.1       3.8       22.0
  Dazza MC                 *Am J Trop Med Hyg* 1993; **48**: 237--242                        Mozambique           178             141            37      64.6       4.5        1.7       29.2
  Cenac A                  *Am J Trop Med Hyg* 1995; **52**: 293--296                        Niger                26               19            7       57.7       7.7       15.4       19.2
  Olbuyide IO              *Trans R Soc Trop Med* Hyg 1997; **91**: 38--41                   Nigeria              64               42            22      48.4       7.8       10.9       32.8
  Kew MC                   *Gastroenterology* 1997; **112**: 184--187                        South Africa         231             201            30      44.6       16.9       8.7       29.9
  Ka MM                    *Dakar Med* 1996; Spec No: 59--62                                 Senegal              64               56            8       34.4       64.1       1.6        0
  Bile K                   *Scand J Infect Dis* 1993; **25**: 559--564                       Somalia              62               53            9       37.1       35.5       4.8       22.6
  Omer RE                  *Trans R Soc Trop Med Hyg* 2001; **95**: 487--491                 Sudan                115              88            27      41.7       10.4       0.9       47.0
  **Continent subtotal**                                                                                       **1864**                                **30.0**   **43.2**   **6.8**   **20.0**
                                                                                                                                                                                           
  NORTH AMERICA                                                                                                                                                                       
  Marrero JA               *J Hepatol* 2005; **42**: 218--224                                United States        70               44            26      7.1        51.4       0.0       41.4
  Davila JA                *Gastroenterology* 2004; **127**: 1372--1380                      United States       2584             1721          863      5.8        13.3       2.9       77.9
  Ding X^c^                *Jpn J Inf Dis* 2003; **56**: 19--22                              United States        65               41            24      15.4       41.5       3.1       40.0
  Hassan MM                *Hepatology* 2002; **36**: 1206--1213                             United States        115              87            28      11.3       19.1       3.5       66.1
  Abe K                    *Hepatology* 1998; **28**: 568--572                               United States        65               40            25      10.8       41.5       1.5       46.2
  Yu MC                    *Hepatology* 1997; **25**: 226--228                               United States        111              67            44      7.2        31.5       1.8       59.5
  Nomura A                 *J Infect Dis* 1996; **173**: 1474--1476                          United States        24               24            0       62.5       0.0        0.0       37.5
  Di Bisceglie             *Am J Gastroenterol* 2003; **98**: 2060--2063                     United States        691             ---           ---      15.5       46.6       4.8       33.1
  Di Bisceglie^a^          *Am J Gastroenterol* 1991; **86**: 335--338                       United States        99               67            32      6.1        12.1       1.0       80.8
  Hasan F^a^               *Hepatology* 1990, **12**: 589--591                               United States        87              ---           ---      27.6       35.6       4.6       32.2
  **Continent subtotal**                                                                                       **3911**                                **8.8**    **21.9**   **3.1**   **66.1**
                                                                                                                                                                                           
  LATIN AMERICA                                                                                                                                                                       
  Miranda EC               *Rev Soc Bras Med Trop* 2004; **37** (Suppl 2): 47--51            Brazil               36               31            5       58.3       0.0        8.3       33.3
  Goncalves CS             *Rev Inst Med Trop Sao Paulo* 1997; **39**: 165--170              Brazil               180             139            41      32.8       21.1       3.9       42.2
  Mondragon Sanchez R      *Hepatogastroenterology* 2005; **52**: 1159--1162                 Mexico               71              ---           ---      8.5        60.6      14.1       16.9
  Ruiz E                   *Rev Gastroenterol Peru* 1998; **18**: 199--212                   Peru                 136             116            20      63.2       0.7        0.0       36.0
  **Continent subtotal**                                                                                        **423**                                **40.7**   **19.4**   **4.7**   **35.2**
                                                                                                                                                                                           
  OCEANA                                                                                                                                                                              
  Yip D^b^                 *World J Gastroenterol* 1999; **5**: 483--487                     Australia            63               43            20      28.6       3.2        4.8       63.5
  **Total**                                                                                                    **30763**                               **38.3**   **29.7**   **7.0**   **25.0**

Studies reporting first generation ELISA.

Studies presumed to have used first-generation ELISA.

Studies reporting only HCV RNA testing.

Data has been expanded since original publication.
